Ipsen to buy Kartos Therapeutics for $450M, gaining Phase 3 myelofibrosis drug navtemadlin
French pharmaceutical company Ipsen announced it will acquire California-based Kartos Therapeutics, paying $450 million upfront. The acquisition gives Ipsen control of navtemadlin, an MDM2 inhibitor currently in Phase 3 trials for intermediate and high-risk myelofibrosis. The deal also includes potential milestone payments of up to $1.3 billion linked to regulatory approval and sales targets, with closing expected in the third quarter.
The news was part of a broader industry roundup that mentioned an FDA pilot program cohort selection and other regulatory updates.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that